Stem Cell Sciences in new FP6 collaboration
Stem Cell Sciences Plc said it is coordinator of a new collaboration that will design bioassays that can be used to discover new candidates for treating cancer, Alzheimer’s disease, stroke and epilepsy.
News
GATC Biotech forms group to develop DNA-based sepsis diagnostic test
GATC Biotech AG, a German DNA sequencing service provider, said it has signed a collaboration agreement with three partners to develop a DNA microarray-based diagnostic test able to detect both bacterial and fungal sepsis-triggering pathogens
Allergy Therapeutics expects FDA clinical trial hold to be lifted
The chairman of Allergy Therapeutics Plc said he expects the FDA hold on its clinical trials of Pollinex Quattro to be lifted in due course.
Omega Pharma spins out its professional health unit with an IPO on Euronext
Omega Pharma NV is spinning out its professional health division, Arseus NV., with an Initial Public Offering (IPO) of 23.5 million shares on the Euronext in Brussels and Amsterdam.
EMEA recommends six drugs for marketing authorisation
A committee of the European Medicine Agency has recommended that six drugs, including one generic medicine, be authorised for marketing in the European Union.
MRC supports women who donate eggs for stem-cell research
The UK Medical Research Council (MRC) said that it will fund a research project from the North East England Stem Cell Institute that involves partially financing in vitro fertilisation (IVF) treatments for women who donate their surplus eggs for stem-cell research.
Novozymes and University College London collaborate on cancer
Researchers at University College London and Novozymes Delta UK Ltd are working together to develop potential therapeutics for cancer.
Oxford BioMedica set to receive €9 million milestone payment
Oxford BioMedica Plc said that it has reached the first development milestone in its collaboration with Sanofi-Aventis to produce a cancer immunotherapy product, leading to a payment of €9 million. The product, TroVax, targets the tumour antigen 5T4 which appears in a wide range of solid tumours.
Evotec acquires Renovis and will apply for NASDAQ listing
Evotec AG has reached an agreement to acquire Renovis Inc of San Francisco, California, in an all stock transaction valued at about $151.8 million
EMEA recommends 17 orphan designations
A committee of the European Medicine Agency has recommended that 17 new products qualify for financial and regulatory incentives because they meet the European criteria for orphan medicines. Orphan products are intended to treat serious or life-threatening diseases that affect not more than 5 out of 10,000 persons in the European Union. Producers of orphan designated drugs may be eligible for grants and regulatory fee reductions.